GALECTIN THERAPEUTICS

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

29 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: GALECTIN THERAPEUTICS INC. - COMMON STOCK

22 Mar 2024 08:45:05 By NetDania Notify

NetDania - New 12 months High: GALECTIN THERAPEUTICS INC. - COMMON STOCK

21 Mar 2024 10:50:02 By NetDania Notify

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

12 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

13 Nov 2023 07:45:52 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

13 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

03 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

23 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

12 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis

03 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

26 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

11 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

07 Sep 2023 11:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

14 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

15 May 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

27 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

18 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

30 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

16 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

02 Mar 2023 07:00:01 By Nasdaq GlobeNewswire